Adjuvant sunitinib for renal cell carcinoma

Longer disease-free survival in phase III trial of sunitinib as adjuvant treatment for kidney cancer

What is the future of proton therapy in the UK and worldwide?

Custirsen shows no survival benefit in metastatic prostate cancer

Benefits of adjuvant chemo for soft tissue sarcoma patients

Significant survival gains for neoadjuvant chemotherapy for high risk soft tissue sarcoma

Cabozantinib over sunitinib for metastatic renal cell carcinoma

Promising results in metastatic bladder cancer using immunotherapy

How can we improve the reliability and quality of cancer registries?

Negative trial results of custirsen for metastatic prostate cancer

Cabozantinib improves PFS in metastatic renal cell carcinoma

Advances for NSCLC in review